<DOC>
	<DOC>NCT00214201</DOC>
	<brief_summary>The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.</brief_summary>
	<brief_title>Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>received a renal transplant, induction with Campath1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone. Recipients of HLAidentical livingdonor renal transplants; PRA value &gt;20% within 30 days of transplant; GFR &lt;40ml/min; multiorgan transplant;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>